IP Verse

Actelion Pharmaceuticals competitive analysis

Loading summary...

Latest patents of Actelion Pharmaceuticals opposed by its competitors

Explore Actelion Pharmaceuticals's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Nov 6, 2025
Patent NumberGrant DateTitleTotal Oppositions
EP4065119
Sep 4, 2024Methods Of Treating Pulmonary Arterial Hypertension4
EP3897646
May 22, 2024Pharmaceutical Composition For The Treatment Of Pulmonary Arterial Hypertension3
EP3256125
Jan 26, 2022Dosing Regimen For A Selective S1P1 Receptor Agonist2
EP3592391
Apr 21, 2021Pharmaceutical Composition Comprising Selexipag1
EP3300729
Oct 9, 2019Therapeutic Compositions Containing Macitentan3
EP2315587
Oct 25, 2017Therapeutic Compositions Containing Macitentan5

Latest PTAB cases involving Actelion Pharmaceuticals

Discover the latest PTAB cases involving Actelion Pharmaceuticals, highlighting their recent legal challenges and patent disputes.

Last updated on: Nov 11, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Actelion Pharmaceuticals

IPR2025-01139Jun 10, 2025UNITED THERAPEUTICSACTELION PHARMACEUTICALSInstitution Denied
IPR2015-00561Jan 13, 2015ACTELION PHARMACEUTICALSICOSFinal Written Decision
IPR2015-00562Jan 13, 2015ACTELION PHARMACEUTICALSICOSFinal Written Decision

Peer Comparison New

IP litigation analysis comparing Actelion Pharmaceuticals with top 3 competitors. Includes complete PTAB case data and opposition data from 2018 onwards.

Last updated on: Nov 6, 2025
CompanyOppositions FiledOppositions FacedPTAB Cases FiledPTAB Cases Faced
ACTELION PHARMACEUTICALS - 1821
GENERICS UK214 - - -
HEXAL573 - -
ICOS - - - 8